• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Early refills now allowed in New Jersey

Article

New Jersey has enacted legislation that requires insurance companies and health plans to provide coverage for the early refill of prescription eye drops at 70% of the predicted days of use.

 

Trenton, NJ-The state of New Jersey has enacted legislation that requires insurance companies and health plans to provide coverage for the early refill of prescription eye drops at 70% of the predicted days of use.

This important patient safety legislation would ensure continuity of therapy for patients with eye and sight problems by allowing the uninterrupted administration of necessary eye medication for patients who are in need of early refills. The New Jersey Academy of Ophthalmology (NJAO), spearheaded by President Cecily Lesko MD, was at the forefront of this legislation, advocating on behalf of New Jersey patients.

“Many diseases of the eye are treated with chronic therapy through use of medications,” said Dr. Lesko. “Glaucoma is the most common. Left untreated, it is one of the leading causes of blindness. With this effort and outcome, proper treatment remains available to more patients who will benefit personally and directly through the treasured gift of sight.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
Video 1 - "Challenging the Definition of Dry Eye- Interpreting Diagnostic Tests"
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.